After years of decline, Croda International is attempting one of the more closely watched turnarounds among FTSE 100 stocks right now.
The specialty chemicals group was once considered a standout performer on the index, with its shares surging after the Covid pandemic on strong demand for lipid ingredients used in vaccines.
That post-pandemic spike drove a sharp rise in sales, but the boom proved short-lived, and the stock has since fallen around 70% from its highs.
Management is now pushing a broad reset of the business, focused on simplification, cost discipline, and a sharper focus on core markets where the group has the strongest competitive advantages.
The three areas identified as central to Croda’s recovery are Beauty, Pharma, and Agriculture, all of which offer more consistent demand and stronger pricing power than some of the group’s other activities.
One of the central diagnoses from management is that costs were allowed to rise faster than sales, a self-inflicted problem compounded by a wave of acquisitions that failed to generate the expected returns.
The company is now pushing for simpler, more disciplined execution, with a sharper innovation focus, closer alignment with customer needs, and greater use of digital tools and AI across manufacturing and supply chains.
The Beauty division is the group’s largest growth engine and represents the clearest test of whether the recovery plan can deliver, having been through a difficult period of weaker demand as customers adjusted to post-pandemic conditions.
Croda is investing in faster commercialisation of new ingredients and co-creation with customers, while also targeting faster-growing markets outside Europe where demand dynamics are more favourable.
If these efforts gain traction, the Beauty segment could shift from being a drag on group performance to a stabilising and potentially re-accelerating contributor to revenue growth.
There are, however, meaningful risks that investors should weigh carefully before drawing conclusions about the pace or scale of any recovery.
The most significant concern is execution, given that Croda is attempting a wide-ranging reset across innovation, costs, and operations after several years of underperformance that will take time to reverse.
Previous acquisitions and expansion efforts have left the business with a higher cost base, and it remains unclear how quickly returns can be lifted back toward the levels the company historically delivered.
Any slowdown in demand from key end markets, particularly Beauty, could also quickly expose lingering margin pressure before the restructuring effort has had time to fully take effect.
Despite these risks, the combination of a sharp share price decline, active management intervention, and a more focused strategic direction makes Croda a recovery story that long-term investors may find difficult to overlook entirely.